In the Netherlands, Koninklijke DSM N.V., the global science-based company active in health, nutrition and materials, agreed to make a $25 million equity investment in Amyris, Inc., the industrial bioscience company. DSM and Amyris will focus on a number of short- to medium-term product development and production opportunities in vitamins and other nutritional ingredients.
Amyris’ technology supports DSM’s strategic markets in health, nutrition and materials, as well as a growing consumer shift to products derived from sustainable sources. For Amyris, DSM’s animal nutrition, human nutrition and consumer health market access and understanding in selecting the right products for the markets provide strategic value.
DSM’s investment translates into about 12 percent of Amyris’ equity and subject to the satisfaction of certain conditions, DSM may invest an additional $25 million in Amyris. The funding will arrive in two tranches and DSM will gain one board seat upon the closing of each tranche.